niacinamide has been researched along with B-Cell Chronic Lymphocytic Leukemia in 12 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In conclusion, sorafenib is active and well tolerated in acute myelogenous leukemia with fms-like tyrosine kinase 3 internal tandem duplication mutation." | 5.15 | Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. ( Andreeff, M; Borthakur, G; Cortes, JE; Faderl, S; Kantarjian, H; Konopleva, M; Mathews, S; Ravandi, F; Verstovsek, S; Wright, JJ; Zhang, W, 2011) |
| "Chemokine receptors expressed on chronic lymphocytic leukemia (CLL) cells regulate the migration of the leukemia cells within the bone marrow (BM), lymphoid organs in collaboration with chemokines." | 2.50 | Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy. ( Fan, L; Han, TT; Li, JY; Xu, W, 2014) |
| "Sorafenib or dasatinib displayed sigmoidal or saturation-type dose-response relationships for apoptosis induction, which were uniform or highly divergent, respectively, among individual CLL samples and therefore might complement each other in their clinical potential for CLL." | 1.38 | Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells. ( Claasen, J; Frenzel, LP; Gehrke, I; Hallek, M; Krause, G; Kuckertz, M; Patz, M; Veldurthy, A; Wendtner, CM, 2012) |
| "Due to the long-lasting course of CLL second cancers can occur in these patients." | 1.34 | [Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination]. ( Bargetzi, M; Puric, E; Schönenberger, A; Sendi, P, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 11 (91.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, TT | 1 |
| Fan, L | 1 |
| Li, JY | 1 |
| Xu, W | 1 |
| Dwojak, M | 1 |
| Bobrowicz, M | 1 |
| Bil, J | 1 |
| Bojarczuk, K | 1 |
| Pyrzynska, B | 1 |
| Siernicka, M | 1 |
| Malenda, A | 1 |
| Lech-Maranda, E | 1 |
| Tomczak, W | 1 |
| Giannopoulos, K | 1 |
| Golab, J | 1 |
| Winiarska, M | 1 |
| Ganghammer, S | 1 |
| Gutjahr, J | 1 |
| Hutterer, E | 1 |
| Krenn, PW | 1 |
| Pucher, S | 1 |
| Zelle-Rieser, C | 1 |
| Jöhrer, K | 1 |
| Wijtmans, M | 1 |
| Leurs, R | 1 |
| Smit, MJ | 1 |
| Gattei, V | 1 |
| Greil, R | 1 |
| Hartmann, TN | 1 |
| Borthakur, G | 1 |
| Kantarjian, H | 1 |
| Ravandi, F | 1 |
| Zhang, W | 1 |
| Konopleva, M | 1 |
| Wright, JJ | 1 |
| Faderl, S | 1 |
| Verstovsek, S | 1 |
| Mathews, S | 1 |
| Andreeff, M | 1 |
| Cortes, JE | 1 |
| Messmer, D | 2 |
| Fecteau, JF | 2 |
| O'Hayre, M | 2 |
| Bharati, IS | 2 |
| Handel, TM | 2 |
| Kipps, TJ | 2 |
| Huber, S | 1 |
| Oelsner, M | 1 |
| Decker, T | 1 |
| zum Büschenfelde, CM | 1 |
| Wagner, M | 1 |
| Lutzny, G | 1 |
| Kuhnt, T | 1 |
| Schmidt, B | 1 |
| Oostendorp, RA | 1 |
| Peschel, C | 1 |
| Ringshausen, I | 1 |
| Audrito, V | 1 |
| Vaisitti, T | 1 |
| Rossi, D | 1 |
| Gottardi, D | 1 |
| D'Arena, G | 1 |
| Laurenti, L | 1 |
| Gaidano, G | 1 |
| Malavasi, F | 1 |
| Deaglio, S | 1 |
| López-Guerra, M | 1 |
| Xargay-Torrent, S | 1 |
| Pérez-Galán, P | 1 |
| Saborit-Villarroya, I | 1 |
| Rosich, L | 1 |
| Villamor, N | 1 |
| Aymerich, M | 1 |
| Roué, G | 1 |
| Campo, E | 1 |
| Montserrat, E | 1 |
| Colomer, D | 1 |
| Kuckertz, M | 1 |
| Patz, M | 1 |
| Veldurthy, A | 1 |
| Gehrke, I | 1 |
| Claasen, J | 1 |
| Frenzel, LP | 1 |
| Wendtner, CM | 1 |
| Hallek, M | 1 |
| Krause, G | 1 |
| Jebaraj, BM | 1 |
| Kienle, D | 1 |
| Bühler, A | 1 |
| Winkler, D | 1 |
| Döhner, H | 1 |
| Stilgenbauer, S | 1 |
| Zenz, T | 1 |
| Sendi, P | 1 |
| Puric, E | 1 |
| Schönenberger, A | 1 |
| Bargetzi, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of BAY 43-9006 (NSC 724772) in Patients With Acute Leukemias, Myelodysplastic Syndromes and Chronic Myeloid Leukemia in Blast Phase[NCT00217646] | Phase 1 | 36 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for niacinamide and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.
Topics: Aminopyridines; Antineoplastic Agents; Benzylamines; Chemokine CXCL12; Clinical Trials as Topic; Cyc | 2014 |
1 trial available for niacinamide and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Female; Humans; Leukemia, Lymphocytic, Chronic, B | 2011 |
10 other studies available for niacinamide and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; C | 2015 |
Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors.
Topics: Antineoplastic Agents; B-Lymphocytes; Chemokine CXCL10; Chemokine CXCL11; Chemokine CXCL9; Chemotaxi | 2016 |
Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib.
Topics: Apoptosis; Benzenesulfonates; Calcium; Cell Survival; Chemokine CXCL12; Dose-Response Relationship, | 2011 |
Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Flow Cytometry; Humans; Leukemia, Lymphocytic, | 2011 |
Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Cell Growth Processes; Dru | 2011 |
Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1).
Topics: Apoptosis; Benzenesulfonates; Cell Survival; Cells, Cultured; Humans; Immunoblotting; Leukemia, Lymp | 2012 |
Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells.
Topics: Benzenesulfonates; Blotting, Western; Cell Movement; Cell Survival; Chemokines; Chemotaxis; Humans; | 2012 |
Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells.
Topics: Benzenesulfonates; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Humans; Lethal Dose 5 | 2012 |
BRAF mutations in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Exons; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles | 2013 |
[Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Bone Neoplasms; Carcinoma | 2007 |